Q-omics provides the consensus-scored KLHL7-DT profile across patient tissues and cancer cell-line models. KLHL7-DT expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, KLHL7-DT is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, KLHL7-DT RNA expression shows 16,507 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight THYM, LUAD, and UVM as cancer lineages where KLHL7-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHL7-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHL7-DT survival associations across molecular data types. KLHL7-DT RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHL7-DT RNA expression–survival associations across cancer types. High KLHL7-DT expression shows unfavorable associations in KIRP and MESO, but favorable associations in THYM, UCS, LUAD and DLBC. The THYM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for KLHL7-DT RNA expression.
This table summarizes KLHL7-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for KLHL7-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHL7-DT shows lower tumor expression in KIRC and higher tumor expression in LUAD, LIHC, HNSC, LUSC and COAD. The LUAD box plot shows higher KLHL7-DT RNA expression in tumor versus normal tissue (log2 FC = +0.769, t-test p < 0.001).
This table shows molecular features associated with KLHL7-DT in patient tissues and cancer cell lines. In patient samples, KLHL7-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
